Novo Nordisk A/S (NYSE:NVO) Shares Bought by Mogy Joel R Investment Counsel Inc.

Mogy Joel R Investment Counsel Inc. raised its stake in Novo Nordisk A/S (NYSE:NVO) by 43.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 154,684 shares of the company’s stock after acquiring an additional 46,500 shares during the quarter. Novo Nordisk A/S makes up approximately 1.2% of Mogy Joel R Investment Counsel Inc.’s investment portfolio, making the stock its 25th largest position. Mogy Joel R Investment Counsel Inc.’s holdings in Novo Nordisk A/S were worth $16,002,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the business. Clarius Group LLC increased its holdings in shares of Novo Nordisk A/S by 0.5% in the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock valued at $1,914,000 after acquiring an additional 93 shares during the last quarter. Tradewinds Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 2.0% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock valued at $513,000 after acquiring an additional 95 shares during the last quarter. Relyea Zuckerberg Hanson LLC grew its stake in Novo Nordisk A/S by 3.2% during the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after buying an additional 99 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its stake in Novo Nordisk A/S by 3.5% during the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after buying an additional 100 shares during the last quarter. Finally, Highlander Capital Management LLC grew its stake in Novo Nordisk A/S by 0.4% during the 4th quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after buying an additional 100 shares during the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded up $1.06 during midday trading on Friday, hitting $126.85. The company had a trading volume of 3,312,457 shares, compared to its average volume of 3,307,405. The company’s 50 day simple moving average is $126.86 and its 200 day simple moving average is $111.98. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The stock has a market cap of $569.24 billion, a price-to-earnings ratio of 46.90, a PEG ratio of 2.10 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. The business had revenue of $9.51 billion during the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. Research analysts anticipate that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were issued a $0.664 dividend. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 49.17%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price target on the stock. UBS Group assumed coverage on Novo Nordisk A/S in a research note on Tuesday, January 16th. They set a “neutral” rating on the stock. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research note on Friday, April 12th. They set an “outperform” rating and a $163.00 price target on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S has a consensus rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.